Applied Genetic Technologies : AGTC Corporate Presentation

This presentation contains forward-looking statements that reflect AGTC's plans, estimates and beliefs, including statements regarding the timing for

reporting data in both its XLRP and ACHM clinical programs, the timing and potential of the Company's pre-clinical programs, the potential of its

partnered programs and collaborations, the potential to partner future programs, and the timing for an impact of its planned manufacturing facilities and the funding needs for these programs. Forward-looking statements include information concerning our possible or assumed future results of operations, including results and timing of our clinical trials and planned clinical trials, business strategies and operations, financing plans, preclinical and clinical product development and regulatory progress, potential growth opportunities, potential market opportunities, the effects of competition and the impact of the COVID-19 pandemic, including the impact on AGTC's ability to enroll patients. Forward-looking statements include all

statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "hopes,"

"intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors. Risks and uncertainties that may cause actual results to differ materially include, among others: gene therapy is still novel with only a few approved treatments so far; AGTC cannot predict when or if it will obtain regulatory approval to commercialize a product candidate or receive reasonable reimbursement; uncertainty inherent in clinical trials and the regulatory review process; risks and uncertainties associated with drug development and commercialization; the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations and financial condition; factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading "Risk Factors" in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission as supplemented by subsequently filed quarterly reports on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management's plans, estimates, assumptions and beliefs only as of the date of this presentation. Except as required by law, we assume

no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those

anticipated in these forward-looking statements, even if new information becomes available in the future.

XLRP: Lead Phase 2/3

Ophthalmology

Candidate

Potential Best-in-Class

Late-Stage Asset

Improvements in visual sensitivity and acuity sustained for at least twelve months

No product-related SAEs

across 100-fold dose

range

Key clinical data readouts

expected in 2022

High-Value

Clinical Programs

ACHMB3 Data

Visual sensitivity and light

discomfort improvements support continued clinical development

Bionic Sight

Partnership

Encouraging signs of

significant improvements in

function vision

Integrated Gene Therapy Platform

Differentiated with

Demonstrated

Capabilities

Broad pre-clinical data

Robust use of disease- specific animal modeling

Novel, patent protected

vector components

Manufacturing

Unmatched

Productivity,

Scalability & Quality

10-fold reduction in

process residuals and

10-fold increase in

productivity

At commercial scale:

40 L ≥ 2000 ophthalmic

doses

		IND ENABLING	PHASE 1/2	PHASE 2/3	NEXT MILESTONE*	Patient Population (approx.)
	OCULAR
	XLRP	RPGR (ORPHAN DRUG)			Skyline 3-month data 2Q 22	20,000 (US and EU)
			Vista interim analysis 1H 23
	ACHM	CNGB3 (ORPHAN DRUG)			3-month Pediatric data both trials 1Q 22
				27,000 (US and EU)
	CNGA3 (ORPHAN DRUG)			EOP2 Feedback 1H 22
	Retinitis Pigmentosa	UNIQUE CHR & NEUROPROSTHETIC		Partnership with Bionic Sight; complete dosing	20,000 (US and EU)
	Dry AMD	COMPLEMENT FACTOR H		IND filing	1,000,000 GA (US)

NEURODEGENERATIVE

FTD

ALS

PROGRANULIN	IND filing; partnering effort	50,000 (US)
		Development candidate; partnering effort	30,000 (US)
C9ORF72

OTOLOGY

Non-Syndromic	GJB2	Partnership with Otonomy; IND 1H 23	200,000 (US and EU)
Hearing Loss

*Anticipated milestones based on calendar year, not AGTC's fiscal year

Capsid Diversity

Promoter

Gene Cassette

Manufacturing

Clinical Development

Targeted capsid	Optimized	Expression of	Unmatched	Patient focus
for each cell	expression in	high-fidelity	productivity and	enhances
type	target cells	gene products	quality	outcomes